Syncona has reported a flat net asset value for its first quarter while concentrating its Capital on late-stage clinical companies and targeting a potential £250m return to shareholders.

Syncona (LSE:SYNC), the FTSE 250 life science Investment company that founds, builds and funds European biotechnology businesses, is midway through a significant strategic shift. Its first-quarter update, covering the three months to 30 June 2026, showed a stable Balance Sheet and a portfolio approaching several important clinical milestones, as the company works towards returning capital to shareholders through mergers, acquisitions and other Liquidity events.

A stable quarter for net assets

Syncona reported net Assets of £1,038.1m at the end of June, equivalent to 170.6p per share, with a NAV return of 0.0% for the quarter. The value of the life science portfolio rose 0.5% to £866.7m, while the capital pool, the cash and liquid resources available for further investment, fell to £171.4m from £198.3m as the company deployed funds into its holdings.

All of the £24.9m invested during the quarter went into late-stage clinical companies. Spur Therapeutics received £7.4m and Resolution Therapeutics £17.5m, consistent with the company's revised investment policy, unveiled alongside its full-year results earlier in 2026, which prioritises backing more mature assets with nearer-term value inflection points.

Clinical progress across the portfolio

There were notable developments across the portfolio. Spur dosed the first patient in GALILEO-3, its Phase III trial of a gene therapy for Gaucher disease, an important step for one of Syncona's larger holdings. Resolution's investment case was reinforced by positive four-year data from the MATCH trial of its macrophage-based therapy for liver cirrhosis.

There were also changes in leadership. At Spur, Michael Parini moved from chief executive to chair, with chief scientific officer Henning Stennicke taking on the role of chief operating officer. Anaveon appointed Eric Zanelli as chief scientific officer and Jill Jene as chief Business officer, while Mosaic named Dr Allison Jeynes as board chair.

Four catalysts before the year end

Syncona has highlighted four potential value inflection points expected by the end of 2026. These are a Phase II/III data readout from Beacon Therapeutics in X-linked retinitis pigmentosa; Phase IIb data from iOnctura in uveal melanoma; commercial traction for Autolus following the US launch of its CAR-T therapy AUCATZYL; and interim Phase I/II data from Resolution in end-stage liver disease.

The outcome of these events is likely to be significant for sentiment towards the shares. Positive data could strengthen the case for partnering deals or sales of portfolio companies, while setbacks could lead to write-downs. Biotechnology valuations remain highly sensitive to clinical results, and private company holdings are also influenced by conditions in public biotech markets and the appetite of larger pharmaceutical companies for acquisitions.

The £250m capital return ambition

Central to Syncona's new strategy is its aim to return up to £250m to shareholders, funded by M&A and liquidity events across the portfolio. The ambition is designed in part to address the discount at which the shares have traded to NAV, a persistent feature for life science investment companies as investors have questioned private biotech valuations.

The broader backdrop has turned more supportive in 2026, with large pharmaceutical groups continuing to pursue acquisitions to replenish their pipelines as patents on major drugs expire. For Syncona, the coming months will test whether its late-stage holdings can deliver the clinical and commercial outcomes needed to convert that environment into realised returns. Its interim results, covering the six months to the end of September, are expected later in the autumn.